EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Repression of PRMT activities sensitize human homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment

Youyou Zhang, Mu Xu, Jiao Yuan, Zhongyi Hu, Junjie Jiang, Yanrong Sun, Jie Huang, Yuxin Wang, Bingwei Wang, Jianfeng Shen, Meixiao Long, Yi Fan und 9 weitere

eLife · 2026

DOI: 10.7554/elife.99225 ↗

Kurz gefasst

Fachartikel in der Zeitschrift eLife, 2026. Verfasst von Youyou Zhang und 20 weiteren Autor:innen. Beteiligte Einrichtung: Center for Women's Health and Reproductive Medicine, University of Pennsylvania, Philadelphia, United States. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Protein-Arginine N-Methyltransferases, Breast Neoplasms, Ovarian Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, Ovarian Cancer Research Alliance.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Therapeutic epigenetic modulation is currently being evaluated in the clinic to sensitize homologous recombination (HR)-proficient tumors to PARP inhibitors. To broaden its clinical applicability and identify more effective combination strategies, we conducted a drug screen combining PARP inhibitors with 74 well-characterized epigenetic modulators targeting five major classes of epigenetic enzymes. Notably, both type I PRMT inhibitors and PRMT5 inhibitors scored highly in combination efficacy and clinical prioritization. PRMT inhibition significantly enhanced PARP inhibitor-induced DNA damage in human HR-proficient ovarian and breast cancer cells. Mechanistically, PRMT suppression downregulates DNA damage repair genes and BRCAness-associated pathways, while also modulating intrinsic innate immune responses within cancer cells. Integrative analysis of large-scale genomic and functional datasets from TCGA and DepMap further supports PRMT1, PRMT4, and PRMT5 as promising therapeutic targets in oncology. Importantly, dual inhibition of PRMT1 and PRMT5 synergistically sensitizes tumors to PARP inhibitors. Collectively, our findings provide strong rationale for the clinical development of PRMT and PARP inhibitor combinations in HR-proficient ovarian and breast cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Poly(ADP-ribose) Polymerase InhibitorsProtein-Arginine N-MethyltransferasesBreast NeoplasmsOvarian NeoplasmsHomologous RecombinationRepressor ProteinsHumansFemaleCell Line, TumorEnzyme Inhibitors

Stichwörter der Autor:innen

PARP inhibitorPRMT inhibitorcancer biologycancer treatmentmouse

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsProtein-Arginine N-MethyltransferasesPRMT5 protein, humanPRMT1 protein, humanRepressor ProteinsEnzyme Inhibitors

Autor:innen und Institutionen

  • Center for Women's Health and Reproductive Medicine, University of Pennsylvania, Philadelphia, United States.
  • Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, United States.
  • Division of Hematology, Department of Internal Medicine, Ohio State University, Columbus, United States.
  • Abramson Cancer Center, University of Pennsylvania, Philadelphia, United States.
  • Department of Radiation Oncology, University of Pennsylvania, Philadelphia, United States.
  • Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, United States.

ORCID-Profile: Lin Zhang, Xiaowen Hu

Förderung

  • NCI NIH HHS
  • National Cancer Institute
  • Ovarian Cancer Research Alliance
  • Foundation for Women’s Cancer
  • Adenoid Cystic Carcinoma Research Foundation
  • Torrey Coast Foundation

Zitieren

APA

Zhang, Y., Xu, M., Yuan, J., Hu, Z., Jiang, J., Sun, Y., Huang, J., Wang, Y., Wang, B., Shen, J., Long, M., Fan, Y., Montone, K. T., Tanyi, J., Kim, S. H., Tavana, O., Vonderheide, R. H., Chan, H. M., Domchek, S., …, & Hu, X. (2026). Repression of PRMT activities sensitize human homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment. eLife. https://doi.org/10.7554/elife.99225

Vancouver

Zhang Y, Xu M, Yuan J, Hu Z, Jiang J, Sun Y, et al. Repression of PRMT activities sensitize human homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment. eLife. 2026. doi:10.7554/elife.99225

BibTeX
@article{Zhang2026,
  author = {Zhang, Youyou and Xu, Mu and Yuan, Jiao and Hu, Zhongyi and Jiang, Junjie and Sun, Yanrong and Huang, Jie and Wang, Yuxin and Wang, Bingwei and Shen, Jianfeng and Long, Meixiao and Fan, Yi and Montone, Kathleen T and Tanyi, Janos and Kim, Sarah H and Tavana, Omid and Vonderheide, Robert H and Chan, Ho Man and Domchek, Susan and Zhang, Lin and Hu, Xiaowen},
  title = {Repression of PRMT activities sensitize human homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment},
  journal = {eLife},
  year = {2026},
  doi = {10.7554/elife.99225}
}
Kostenlos starten →